Arcus Biosciences, Inc. Accrued Income Taxes, Current
Arcus Biosciences, Inc. (RCUS) had Accrued Income Taxes, Current of $3.00 million as of 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedIncomeTaxesCurrent · last filed 2023-11-07
- 2023-09-30: Accrued Income Taxes, Current $3.00M.
- 2023-06-30: Accrued Income Taxes, Current $2.00M.
- 2023-03-31: Accrued Income Taxes, Current $1.00M.
- 2022-12-31: Accrued Income Taxes, Current $0.00.
| Period end | Accrued Income Taxes, Current | Accrued Income Taxes, Current as first filed |
|---|---|---|
| 2023-09-30 | $3.00M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $2.00M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $1.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-09-30 | $18.00K 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $18.00K 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $2.82M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $2.00M 10-K · filed 2023-02-28 | $1.81M 10-K · filed 2022-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |